PA
ALNY icon

Perceptive Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Perceptive Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-420,000
Closed -$45K – 134
2017
Q3 		$45K Buy
+420,000
New +$35.8M ﹤0.01% 137

Other funds holding ALNY

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Perceptive Advisors's ALNY Position: Q3 2022 in Review

Perceptive Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 172,991 shares — an estimated $25.2M sold.

Perceptive Advisors first reported a position in ALNY in Q1 2014 and held it in 12 quarters. The position peaked at $210M in Q3 2017. 496 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Perceptive Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Perceptive Advisors sold 172,991 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $25.2M.
  • Perceptive Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • Perceptive Advisors's Alnylam Pharmaceuticals position peaked at $210M in Q3 2017.
  • 496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Perceptive Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.